Brief Report: Prognostic Value of Kaposi Sarcoma Herpes Virus–Associated Clinical Symptom Scores in HIV-Associated Kaposi Sarcoma

BACKGROUND: Kaposi sarcoma herpes virus (KSHV)-associated inflammatory cytokine syndrome (KICS) is defined by clinical, laboratory, and radiographic findings and KSHV viremia. Whether the presenting clinical symptoms of KICS have prognostic value in patients with HIV-associated Kaposi sarcoma (HIV-KS) initiating therapy is unknown. SETTING: Two prospective clinical trials were conducted among participants with mild-to-moderate (A5264/AMC067) and advanced (A5263/AMC066) HIV-KS in low-income and middle-income countries. All participants received antiretroviral therapy, and chemotherapy was given according to the randomly assigned treatment arm. METHODS: We developed a Kaposi sarcoma clinical symptom score (KSCS score), derived from the previously described KICS definition to determine whether the score could inform prognosis. The score ranging from 0 to 3 was based on increasing severity of clinical manifestations. We evaluated the impact of baseline KSCS score on progression-free and overall survival using Cox proportional hazard regression. RESULTS: Of 190 participants in A5264/AMC067 and 329 in A5263/AMC066, 150 (78.9%) and 239 (72.6%) had KSCS score ≥1 and 15 (7.9%) and 95 (28.9%) had KSCS score 3, respectively. Independent of the treatment arm, participants with KSCS score 3 had a higher risk of death (A5264/AMC067: adjusted hazard ratio (aHR) = 9.17; 95% CI: 3.60 to 23.41; A5263/AMC066: aHR = 2.99; 95% CI: 1.69 to 5.28) and shorter progression-free survival (A5264/AMC067: aHR = 2.36 95% CI: 1.26 to 4.43; A5263/AMC066: aHR = 2.31; 95% CI: 1.23 to 3.60) compared with those with KSCS score ≤2. CONCLUSIONS: KSCS score symptoms are common, especially in advanced HIV-KS. KSCS score 3 is associated with higher risk of progressive KS disease or death, despite treatment with antiretrovirals and chemotherapy. This population may benefit from improved diagnostic and management options.

Authors

Institutions

Publication Details

Journal
JAIDS Journal of Acquired Immune Deficiency Syndromes
Published
2026-11-12
DOI
https://doi.org/10.1097/qai.0000000000003942
Primary Topic
Viral-associated cancers and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Brief Report: Prognostic Value of Kaposi Sarcoma Herpes Virus–Associated Clinical Symptom Scores in HIV-Associated Kaposi Sarcoma

Aggrey Bukuru, Mina C. Hosseinipour, Evangeline Wawira Njiru, Thomas Campbell et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes
Viral-associated cancers and disorders
article

Brief Report: Prognostic Value of Kaposi Sarcoma Herpes Virus–Associated Clinical Symptom Scores in HIV-Associated Kaposi Sarcoma

Aggrey Bukuru, Mina C. Hosseinipour, Evangeline Wawira Njiru, Thomas Campbell, Rosie Mngqbisa, Scott V. Adams, Deborah Langat, Carlee Moser, Henriette Burger, Margaret Ziona Borok, Wadzanai P. Samaneka, Naftali Wisindi Busakhala, John D. MacRae, Thomas S. Uldrick, Susan E. Krown, Maganizo Chagomerana, Brenda Hoagland, Kelvin Roland Mubiru, Triin Umbleja, McNeil Ngongondo, Noluthando Mwelase, Mulinda Nyirenda, Michael D. Hughes, Minhee Kang
article en

Abstract

BACKGROUND: Kaposi sarcoma herpes virus (KSHV)-associated inflammatory cytokine syndrome (KICS) is defined by clinical, laboratory, and radiographic findings and KSHV viremia. Whether the presenting clinical symptoms of KICS have prognostic value in patients with HIV-associated Kaposi sarcoma (HIV-KS) initiating therapy is unknown. SETTING: Two prospective clinical trials were conducted among participants with mild-to-moderate (A5264/AMC067) and advanced (A5263/AMC066) HIV-KS in low-income and middle-income countries. All participants received antiretroviral therapy, and chemotherapy was given according to the randomly assigned treatment arm. METHODS: We developed a Kaposi sarcoma clinical symptom score (KSCS score), derived from the previously described KICS definition to determine whether the score could inform prognosis. The score ranging from 0 to 3 was based on increasing severity of clinical manifestations. We evaluated the impact of baseline KSCS score on progression-free and overall survival using Cox proportional hazard regression. RESULTS: Of 190 participants in A5264/AMC067 and 329 in A5263/AMC066, 150 (78.9%) and 239 (72.6%) had KSCS score ≥1 and 15 (7.9%) and 95 (28.9%) had KSCS score 3, respectively. Independent of the treatment arm, participants with KSCS score 3 had a higher risk of death (A5264/AMC067: adjusted hazard ratio (aHR) = 9.17; 95% CI: 3.60 to 23.41; A5263/AMC066: aHR = 2.99; 95% CI: 1.69 to 5.28) and shorter progression-free survival (A5264/AMC067: aHR = 2.36 95% CI: 1.26 to 4.43; A5263/AMC066: aHR = 2.31; 95% CI: 1.23 to 3.60) compared with those with KSCS score ≤2. CONCLUSIONS: KSCS score symptoms are common, especially in advanced HIV-KS. KSCS score 3 is associated with higher risk of progressive KS disease or death, despite treatment with antiretrovirals and chemotherapy. This population may benefit from improved diagnostic and management options.

JAIDS Journal of Acquired Immune Deficiency SyndromesVol. 101(12)
University of North Carolina at Chapel Hill (US), Memorial Sloan Kettering Cancer Center (US), Harvard University (US), Johns Hopkins University (US), Moi University (KE), University of Zimbabwe (ZW), University of the Witwatersrand (ZA), Stellenbosch University (ZA), Asociación Civil Impacta Salud y Educación (PE), Tygerberg Hospital (ZA), Kenya Medical Research Institute (KE), Fred Hutch Cancer Center (US), Hutchinson Centre Research Institute in Uganda (UG), King Edward VIII Hospital (ZA), Instituto Evandro Chagas (BR), Joint Clinical Research Centre (UG), Kamuzu University of Health Sciences (MW), Instituto Nacional de Infectologia Evandro Chagas (BR), University of Colorado Anschutz Medical Campus (US), Fundação Oswaldo Cruz (BR), University of Colorado Denver (US)
Good health and well-being
Viral-associated cancers and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon